Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Long-term Extension Study of S-877489 (lisdexamfetamine) in Pediatric ADHD
jRCT2080222082Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Shionogi & Co., Ltd. Primary endpoint: Safety over 53 weeks. Started May 2013; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2080222082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222082.